Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

DECN to Provide Updates on the Progress of Our GenViro! Covid-19 Test Kits on Thursday April 23
BiotechnologyCompany Update

DECN to Provide Updates on the Progress of Our GenViro! Covid-19 Test Kits on Thursday April 23

April 21, 2020 9:15 AM

COMPANY WILL DETAIL CURRENT PROGRESS OF FDA EUA WAIVER, FILING OF 2ND EUA FOR AT-HOME USE KIT, & HUGE RESPONSE FROM AMERICAN COMPANIES LOOKING TO BUY 1ST IN LINE LOS ANGELES, CA / ACCESSWIRE / April 21, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc. the manufacturers and design specifiers for the GenViro! Covid-19 Swift Kit, is an 18-year old, diabetes and now disease testing...

Read more
Memgen Announces Exclusive License Agreements With Moffitt Cancer Center to Develop Innovative Cancer Immunotherapies
BiotechnologyPartnerships

Memgen Announces Exclusive License Agreements With Moffitt Cancer Center to Develop Innovative Cancer Immunotherapies

April 21, 2020 6:00 AM

HOUSTON, TX / ACCESSWIRE / April 21, 2020 / Memgen, a private biotechnology company developing innovative immuno-oncology drugs and immune therapeutics, announced today that it has entered into technology licensing agreements with the Moffitt Cancer Center, a premier center for cancer research and care. The agreements cover intellectual property developed jointly by scientists at Memgen and Moffitt, including Memgen’s lead product, MEM-288,...

Read more
Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders
BiotechnologyPartnerships

Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

April 20, 2020 9:00 AM

TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a leading Swiss pharmaceutical development company, for an exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications. The...

Read more
Dyadic to Present and Participate in COVID-19 Panel at the Planet MicroCap Showcase Virtual Investor Conference 2020
BiotechnologyConferences

Dyadic to Present and Participate in COVID-19 Panel at the Planet MicroCap Showcase Virtual Investor Conference 2020

April 20, 2020 8:00 AM

JUPITER, FL / ACCESSWIRE / April 20, 2020 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will be presenting at the Planet MicroCap Showcase...

Read more
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi-Target Binding of DARPin(R) Proteins to Neutralize SARS-CoV-2 Virus
BiotechnologyCompany UpdateInvestor Relations

Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi-Target Binding of DARPin(R) Proteins to Neutralize SARS-CoV-2 Virus

April 19, 2020 6:50 PM

First trispecific anti-COVID-19 therapeutic program: targets three parts of the viral "spike" protein with one drug candidate for broad inhibition of infection and mitigation of future drug resistance Initial testing performed in collaboration with the Swiss Federal Office for Civil Protection confirmed deep neutralization potential; candidate testing underway on live virus DARPin® technology expected to allow production...

Read more
Sanara MedTech Inc. Announces an Update on the Execution of its Strategy
BiotechnologyCompany Update

Sanara MedTech Inc. Announces an Update on the Execution of its Strategy

April 17, 2020 9:00 AM

FORT WORTH, TX / ACCESSWIRE / April 17, 2020 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara" or the "Company") (OTCQB:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today an update on the execution of the Company's strategy. Record First Quarter 2020 Revenue and COVID-19 Impact For the first quarter of 2020, the Company generated revenues of...

Read more
Nanalysis to Present at the Planet MicroCap Virtual Showcase Investor Conference 2020
BiotechnologyConferences

Nanalysis to Present at the Planet MicroCap Virtual Showcase Investor Conference 2020

April 16, 2020 7:05 PM

CALGARY, ALBERTA, CANADA / ACCESSWIRE / April 16, 2020 / Nanalysis Scientific Corp. ("Nanalysis") (TSXV: NSCI)(OTCQX:NSCIF)(FRA: 1N1) is excited to announce that it will be participating in the Planet MicroCap Virtual Showcase 2020 on Wednesday, April 22. Mr. Sean Krakiwsky, CEO of Nanalysis will be hosting an investor presentation, answering questions from investors, participating in one-on-one investor calls, and participating in a panel...

Read more
Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer
BiotechnologyManagement Changes

Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer

April 16, 2020 12:20 PM

PARIS, FRANCE / ACCESSWIRE / April 16, 2020 / Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today announced the appointment of Dr. David Horn Solomon as Chief Executive Officer of Pharnext, effective immediately. Dr. Solomon will also be proposed to join the Board of Directors at...

Read more
Tetra Receives its 4th FDA Orphan Drug Designation
BiotechnologyRegulatory

Tetra Receives its 4th FDA Orphan Drug Designation

April 16, 2020 8:00 AM

Tetra's PPP004 cannabinoid drug receives Orphan Drug Designation for the Treatment of Epidermolysis Bullosa OTTAWA / ACCESSWIRE / April 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP);(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its cannabinoid PPP004 (THC-CBD) in the...

Read more
Analytical Validation of Cofactor Genomics' Immune Profiling Assay Published in Journal of Molecular Diagnostics
BiotechnologyCompany Update

Analytical Validation of Cofactor Genomics' Immune Profiling Assay Published in Journal of Molecular Diagnostics

April 16, 2020 8:00 AM

Paper is first peer-reviewed publication of ImmunoPrism performance SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2020 / Today, Cofactor Genomics announced the peer-reviewed publication of an analytical validation study demonstrating the performance of its novel RNA-based immune profiling assay, ImmunoPrism®, in the April 2020 issue of the Journal of Molecular Diagnostics. The paper is the first public disclosure of the company's proprietary...

Read more
Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit
BiotechnologyConferences

Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit

April 15, 2020 8:35 AM

Presentation with live audio webcast on Wednesday, April 22 at 11:30 AM ET, immediately followed by an interactive Q&A session FRAMINGHAM, MA / ACCESSWIRE / April 15, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced that Jeffrey Eisenberg,...

Read more
Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program
BiotechnologyRegulatory

Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program

April 15, 2020 8:00 AM

Tetra's PPP003 cannabinoid drug receives Orphan Drug Designation for the Prevention of Proliferative Vitreoretinopathy OTTAWA / ACCESSWIRE / April 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its synthetic cannabinoid PPP003...

Read more
Afecta Pharmaceuticals Joins Battle Against COVID-19
BiotechnologyCompany Update

Afecta Pharmaceuticals Joins Battle Against COVID-19

April 14, 2020 8:00 AM

IRVINE, CA / ACCESSWIRE / April 14, 2020 / Afecta Pharmaceuticals, a company focused on developing drugs that modulate the immune system announced that it has been invited to submit two of its lead drug candidates to the National Institute of Health to be evaluated for initiation of pre-clinical and potential clinical testing for treatment of 2019 novel Coronavirus (2019-nCoV). The compounds were identified using PharmetRx®, Afecta's...

Read more
Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License
BiotechnologyCompany Update

Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License

April 14, 2020 8:00 AM

DEA Renews Schedule 1 License for Scottsdale Research Institute (Plenitude clinical site) OTTAWA / ACCESSWIRE / April 14, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Dr. Sue Sisley's Scottsdale Research Institute received the renewal of its Schedule 1 license from the US Drug Enforcement Agency (DEA). The receipt...

Read more
Apollo Endosurgery Announces Completion of the US Post-Approval Study for the Orbera(R) Intragastric Balloon System
BiotechnologyCompany Update

Apollo Endosurgery Announces Completion of the US Post-Approval Study for the Orbera(R) Intragastric Balloon System

April 13, 2020 9:00 AM

AUSTIN, TX / ACCESSWIRE / April 13, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures announced today that the US Food and Drug Administration (FDA) has completed the review of the final Post-Approval Study (PAS) Report for the Orbera Intragastric Balloon System and accepted that all post-approval study requirements have been fulfilled. The...

Read more
NascentBiotech's Independent Consultants Have Begun Research on Pribumumab as a Potential Therapeutic Agent Against (Coronavirus) Covid-19
BiotechnologyCompany Update

NascentBiotech's Independent Consultants Have Begun Research on Pribumumab as a Potential Therapeutic Agent Against (Coronavirus) Covid-19

April 7, 2020 4:35 PM

SAN DIEGO, CA / ACCESSWIRE / April 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), today announced that two independent consultants retained by the Company have begun preliminary research on a possible treatment for patients infected with the Coronavirus. An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential...

Read more
Informa PLC - Skipta Launches COVID-19 Forum & Lecture Series
BiotechnologyRegulatory

Informa PLC - Skipta Launches COVID-19 Forum & Lecture Series

April 6, 2020 12:45 PM

Skipta Launches COVID-19 Focus Area And Lecture Series For Healthcare Practitioners Forum for Coronavirus Information Sharing Will Utilize Pharma Intelligence Product Insights and Skipta's Vast Network of Healthcare Professionals NEW YORK, NY / ACCESSWIRE / April 6, 2020 / Skipta, the leading social network of specialized online medical communities for verified healthcare professionals including Oncology Nation, Doctor Unite, and...

Read more
HemaGenetics Technologies Applies Temporary Exemption (Group A) from Certain Corporate Finance Requirements under BC Instrument 51-515
BiotechnologyCompany Update

HemaGenetics Technologies Applies Temporary Exemption (Group A) from Certain Corporate Finance Requirements under BC Instrument 51-515

April 6, 2020 9:00 AM

VANCOUVER, BC / ACCESSWIRE / April 6, 2020 / HemaGenetics Technologies Corp. (the "Company"), due to ongoing non-essential business shut down for COVID-19 measures taken by the Province of British Columbia, is exempt from Group A filings and delaying its annual financial statements release and filing on SEDAR as required under section 4.2 of NI 51-102 until June 1, 2020. As required under section 10 of BC Instrument 51-515, the Company...

Read more
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada
BiotechnologyCompany Update

GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada

April 6, 2020 9:00 AM

LAS VEGAS / ACCESSWIRE / April 6, 2020 / GB Sciences, Inc. (OTCQB:GBLX), is pleased to announce that the company's Canadian entity, GBS Global Biopharma, Inc. (GBS), signed an Amendment to their Agreement with the National Research Council of Canada (NRC). The NRC has demonstrated that the company's PD formulations were able to reduce behavioral changes associated with the loss of dopamine-producing neurons, which underlies the pathology of...

Read more
American CryoStem to Develop ATCELL(TM) Clinical Study for  Duchene Muscular Dystrophy with RACEMD
BiotechnologyCompany Update

American CryoStem to Develop ATCELL(TM) Clinical Study for Duchene Muscular Dystrophy with RACEMD

April 2, 2020 7:40 AM

EATONTOWN, NJ / ACCESSWIRE / April 2, 2020 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has that it has entered into a license and collaboration agreement to apply American CryoStem technologies for the development therapy in Duchenne...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?